Aldeyra Therapeutics (ALDX) EBT (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly EBT came in at -$3.5 million in Q1 2026, up 80.38% YoY from -$1.9 million in Q1 2025, and up 47.88% on a QoQ basis from -$6.6 million in Q4 2025.
Aldeyra Therapeutics (ALDX) EBT (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of EBT data on file, last reported at -$3.5 million in Q1 2026.
- Quarterly EBT rose 80.38% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.6 million (up 52.23% YoY) and the FY2025 annual result came in at -$38.5 million, up 34.45% from the prior year.
- EBT advanced to -$3.5 million in Q1 2026, from -$6.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$3.5 million in Q1 2026 to a low of -$41.5 million in Q1 2023.
- A 5-year average of -$16.0 million and a median of -$15.9 million in 2024 frame the typical range for EBT.
- The widest YoY moves for EBT: up 80.52% in 2024, down 263.5% in 2024.
- Tracing ALDX's EBT over 5 years: stood at -$13.2 million in 2022, then surged by 66.67% to -$4.4 million in 2023, then slumped by 263.5% to -$15.9 million in 2024, then soared by 58.43% to -$6.6 million in 2025, then jumped by 47.88% to -$3.5 million in 2026.
- The last three EBT figures came in at -$3.5 million (Q1 2026), -$6.6 million (Q4 2025), and -$14.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | -5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.43 Mn |
| Mar 31, 2026 | -3.45 Mn |
| Dec 31, 2025 | -6.62 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -10.49 Mn |
| Mar 31, 2025 | -17.60 Mn |
| Dec 31, 2024 | -15.93 Mn |
| Sep 30, 2024 | -22.02 Mn |
| Jun 30, 2024 | -16.85 Mn |
| Mar 31, 2024 | -8.08 Mn |
| Dec 31, 2023 | -4.38 Mn |
| Sep 30, 2023 | -15.18 Mn |
| Jun 30, 2023 | -25.96 Mn |
| Mar 31, 2023 | -41.50 Mn |
| Dec 31, 2022 | -13.15 Mn |
| Sep 30, 2022 | -19.03 Mn |
| Jun 30, 2022 | -18.97 Mn |
| Mar 31, 2022 | -18.58 Mn |
| Dec 31, 2021 | -15.35 Mn |
| Sep 30, 2021 | -27.38 Mn |